2024-517283-28-00招募中2 期
T-Guard against Autoreactive T cells in Systemic sclerosis: Erasion and Resolution (TASER)
Philikos B.V.1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2025年2月10日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Incidence of Grade 3 or higher adverse events (AEs), based on CTCAE v5, occurring in the period from the first T-Guard infusion until 28 days after the last T-Guard administration.
研究概览
简要总结
To evaluate the safety of T-Guard in patients with early diffuse cutaneous systemic sclerosis (dcSSc), evaluated in all 13 study participants
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Aged between 18-75 at the time of signing informed consent.
- •With early dcSSc, defined as skin involvement above and below elbows and/or knees, disease duration ≤36 months from first non-Raynaud phenomenon.
- •Modified Rodnan skin scores (MRSS) scores ≥15
- •Progressive skin or musculoskeletal (MKS)disease, e.g. worsening of skin with new areas of involvement or tendon friction rubs (TFR), with either Health Assessment Questionnaire Disability Index (HAQ-DI) >1.0 or elevated erythrocyte sedimentation rate (ESR)/C-reactive protein (CRP).
- •Interstitial lung disease (ILD) with forced vital capacity (FVC) 50-<80% predicted or lung diffusion testing (DLCO)(Hb corrected) 45-75% or >10% lung involvement on visual rad high-resolution computed tomography (HRCT) scan or those with progressive ILD, defined as progressive pulmonary fibrosis (PPF)-ILD in: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851481/.
- •Participants should have failed at least one established systemic immunosuppressive treatment for dcSSc (e.g., MTX, MMF , azathioprine, rituximab, tocilizumab, intravenous immunoglobulin [IVIG], or cyclophosphamide), each tried for at least 3 months, and: a. Have received treatment with MTX or MMF for at least 3 months prior to enrollment, with the dose stable for at least 8 weeks prior to enrollment; and b. Be able and willing, in the opinion of the investigator, to continue this background therapy at the stable dose throughout the study, unless dose reduction or discontinuation is clinically indicated due to adverse events.
- •Participants should have given written informed consent
排除标准
- •Creatinine greater than or equal to 2mg/dL or creatinine clearance less than 60 mL/min or requiring hemodialysis. History or presence of glomerulonephritis, acute tubular necrosis, and/or interstitial nephritis or clinically significant findings as determined by urinalysis at screening
- •White blood cell count (WBC) <3000 µl
- •On continuous oxygen therapy
- •Significant gastrointestinal (GI) dysmotility requiring total parenteral nutrition or G or J tube
- •Latent infection with mycobacterium tuberculosis, unless history of treatment.
- •Known active infection with Hepatitis B, C, or E at screening (prior infections are not excluded), HIV or HTLV1 positivity.
- •Malignancy within the past 5 years, except for non-melanoma skin cancer or cervical cancer situ.
- •Vascular prosthesis.
- •Need for mechanical ventilation and/or vasopressor support or requiring hemodialysis.
- •Uncontrolled infection (infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present) are not eligible for this trial.
- •Known hypersensitivity to any of the components of murine monoclonal antibodies (mAb), or Recombinant Ricin Toxin A-chain (RTA).
- •Platelets <100,000/mm3
- •Participants who continue to receive any systemic treatment for systemic sclerosis, other than MTX or MMF, including but not limited to azathioprine, cyclosphosphamide, IVIG, rituximab, and tocilizumab, within three months prior to the baseline visit will be excluded. Continuation of oral corticosteroids (≤10 mg/day of prednisone or equivalent) and nonsteroidal anti-inflammatory drugs (NSAIDs) is permitted if the participant is on a stable dose for at least two weeks prior to and including the baseline visit.
- •Evidence of heart failure defined as left ventricular ejection fraction (LVEF) <45% as assessed by either echocardiography or multigated acquisition (MUGA) scan in the last 6 months
- •Echocardiographic features consistent with pulmonary hypertension, unless right heart catheterization (RHC) is normal
- •Moderate to severe restrictive lung disease defined as FVC <50% predicted and/or DLCO <50% predicted and presence of ILD on HRCT
- •Patients who have been diagnosed with scleroderma renal crisis (SRC) or another cause TMA anytime during their lifetime.
- •Albumin of less than or equal to 30 g/L
- •Creatine kinase (CK) level greater than 5 times the upper limit of normal (ULN)
- •Hemoglobulin (Hb) <9 g/dl
结局指标
主要结局
Incidence of Grade 3 or higher adverse events (AEs), based on CTCAE v5, occurring in the period from the first T-Guard infusion until 28 days after the last T-Guard administration.
Incidence of Grade 3 or higher adverse events (AEs), based on CTCAE v5, occurring in the period from the first T-Guard infusion until 28 days after the last T-Guard administration.
次要结局
- Incidence of AEs occurring during 180 days after treatment start
- Incidence of infectious AEs occurring during 180 days after treatment start
- Incidence of SAEs occurring during 180 days after treatment start, and - if considered related to T-Guard treatment - occurring in the period of 180 until 365 days after treatment start
- Incidence of AESIs occurring during 180 days after treatment start, and - if considered related to T-Guard treatment - occurring in the period of 180 until 365 days after treatment start: hypoalbuminemia; thrombocytopenia; microangiopathy.
- All-cause mortality during 365 days after treatment start
- Immunogenicity of T-Guard
- Pharmacokinetics of T-Guard
- Achieving revised CRISS-25 scores at study day 90, 180, 270 and 365 compared to baseline.
- Achieving revised CRISS-50 scores at study day 90, 180, 270 and 365 compared to baseline.
- Achieving revised CRISS-75 scores at study day 90, 180, 270 and 365 compared to baseline.
- Achieving revised CRISS-100 scores at study day 90, 180, 270 and 365 compared to baseline.
- mRSS at study day 36, 90, 180, 270 and 365 compared to baseline.
- Pulmonary function test results (FVC and DLCO % predicted) at study day 180 and 365 compared to baseline.
- HRCT quantification at at study day 180 and 365 compared to baseline.
- Other patient reported measures of function and Quality of Life questionnaires: SHAQ, SF-36, UCLA SCTC GIT 2.0 and EQ5d at study day 36, 90, 180, 270 and 365 compared to baseline.
- Organ worsening as defined in Step 1 of the revised CRISS- 25 score during 365 days after treatment start.
研究者
Ypke van Oosterhout
Scientific
Philikos B.V.
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs. SCLEROCAR2024-519511-33-00Centre Hospitalier Universitaire De Montpellier6
进行中（未招募）
1/2 期
SCTC21C 治疗浆细胞驱动的自身免疫性疾病患者的 I/II 期临床试验CTR2024434399
招募中
不适用
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic MalignanciesNCT07285668University of Wisconsin, Madison38
进行中（未招募）
2 期
在中重度特应性皮炎患者中评价试验性化合物的疗效和安全性的平台研究CTR2025328714
进行中（未招募）
2 期
在中重度特应性皮炎患者中评价试验性化合物的疗效和安全性的平台研究CTR2025328714